Karyopharm – SENTRY Phase 3 Full Data in Frontline Myelofibrosis

Summary Karyopharm delivered one of the most important myelofibrosis datasets of 2026. In the Phase 3 SENTRY study, selinexor plus ruxolitinib nearly doubled spleen response rates versus ruxolitinib alone (49.8% vs 28.0%) and generated an early overall survival signal (HR 0.43). However, the trial missed…